author-photo

Suzette Girgis

Janssen Pharmaceutica

17

Papers

206

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
P-001: Modulation of soluble B-cell maturation antigen levels in patients with relapsed and/or refractory multiple myeloma after treatment with teclistamab and talquetamab

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer.

2021 Prostate Cancer and Prostatic Diseases
Show All
- Source
- Cite
- Save
Citations (1)
Exploratory Pharmacokinetic/Pharmacodynamic and Tolerability Study of BCMAxCD3 in Cynomolgus Monkeys

2016 Blood
Show All
- Source
- Cite
- Save
Citations (10)
Evaluation of JNJ-26489112 in patients with photosensitive epilepsy: A placebo-controlled, exploratory study ,

2014 Epilepsy Research
Show All
- Source
- Cite
- Save
Citations (7)
Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma

2012 Clinical Pharmacokinectics
Show All
- Source
- Cite
- Save
Citations (65)